During the past decade, Qhakaza Mbokodo conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Qhakaza Mbokodo" #1 sponsor was "International Partnership for Microbicides, Inc." with 5 trials, followed by "Janssen Vaccines & Prevention B.V." with 2 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials sponsored, "Wits Health Consortium (Pty) Ltd" with 2 trials sponsored and "CONRAD" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Qhakaza Mbokodo" #1 collaborator was "Bio Analytical Research Corporation" with 2 trials as a collaborator, "BioVac" with 2 trials as a collaborator, "Biocair" with 2 trials as a collaborator, "Clinical Laboratory Services" with 2 trials as a collaborator and "Dis-Chem Pharmacy" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Qhakaza Mbokodo" are "HIV Infections" (7 trials), "COVID-19" (2 trials), "SARS-CoV-2" (2 trials), "Acquired Immunodeficiency Syndrome" (1 trials) and "HIV Prevention" (1 trials). Many other conditions were trialed in "Qhakaza Mbokodo" in a lesser frequency.

Most popular intervention types in "Qhakaza Mbokodo" are "Biological" (6 trials), "Drug" (5 trials), "Other" (5 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Dapivirine" (2 trials), "Sample collection" (2 trials), "ALVAC-HIV (vCP2438)" (1 trials) and "Ad26.COV2.S" (1 trials). Other intervention names were less common.

The vast majority of trials in "Qhakaza Mbokodo" are 8 trials for "Female" genders and 7 trials for "All" genders.

Currently, there are NaN active trials in "Qhakaza Mbokodo". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Qhakaza Mbokodo, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Qhakaza Mbokodo, 3 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".